Skip to main content

Table 2 Sarcoma crude and age-standardized incidence rate per 100,000 person-years according to topographic, genomic and histological groups by sex. FRANCIM network data 2010–2013 (19 registries)

From: Incidence and time trends of sarcoma (2000–2013): results from the French network of cancer registries (FRANCIM)

 

Median Age

Male

Female

Overall

CIR

ASR-W (segi)

ASR-E

ASR-US

CIR

ASR-W (segi)

ASR-E

ASR-US

CIR

ASR-W (segi)

ASR-E

ASR-US

Sarcomas by topographic groups

 Soft tissue

65

3.70

2.43

3.12

3.31

2.90

1.91

2.34

2.38

3.30

2.15

2.68

2.78

 Bone

47

1.20

1.09

1.16

1.17

0.90

0.85

0.87

0.88

1.10

0.96

1.01

1.01

 Skin

54

1.00

0.70

0.88

0.91

0.60

0.46

0.54

0.54

0.80

0.59

0.72

0.73

 Viscera

  Gastro-intestinal organs

69

1.10

0.65

0.91

0.95

1.00

0.57

0.77

0.79

1.10

0.58

0.81

0.84

  Female genital organs

62

–

–

–

–

1.00

0.62

0.82

0.81

1.00

0.62

0.82

0.81

  Other visceral organs

65

0.40

0.26

0.33

0.33

0.50

0.28

0.36

0.37

0.40

0.26

0.34

0.35

  Others anatomic sites

55

0.10

0.15

0.13

0.13

0.10

0.10

0.10

0.10

0.10

0.10

0.10

0.10

Sarcomas by genomic groups

 Complex genomic alterations

65

2.80

1.78

2.30

2.43

3.10

1.93

2.44

2.47

2.90

1.87

2.38

2.45

MDM2 amplification

68

0.50

0.30

0.42

0.45

0.30

0.18

0.23

0.23

0.40

0.23

0.31

0.33

 Mutations

68

1.10

0.66

0.87

0.90

1.00

0.58

0.76

0.77

1.00

0.62

0.80

0.83

 Recurrent translocations

46

1.30

1.23

1.30

1.30

1.60

1.44

1.56

1.54

1.50

1.34

1.44

1.43

 Undefined/Miscellaneous alterations

65

1.90

1.27

1.62

1.70

1.20

0.73

0.90

0.94

1.60

0.97

1.22

1.26

Sarcomas by histologic groups

 Unclassified sarcomaa

69

1.30

0.71

1.00

1.08

1.10

0.62

0.82

0.85

1.20

0.65

0.90

0.94

 Leiomyosarcoma

66

0.80

0.43

0.62

0.68

1.30

0.74

0.99

0.99

1.00

0.58

0.79

0.81

 GIST

69

0.90

0.52

0.75

0.78

0.90

0.47

0.65

0.67

0.90

0.50

0.70

0.72

 Liposarcoma

67

0.90

0.48

0.68

0.72

0.50

0.28

0.37

0.37

0.70

0.38

0.51

0.53

Dedifferentiated liposarcoma

69

0.50

0.24

0.35

0.38

0.30

0.11

0.16

0.16

0.40

0.17

0.25

0.26

Round cell \ Myxoid liposarcoma

51

0.20

0.13

0.16

0.16

0.10

0.09

0.11

0.11

0.10

0.10

0.12

0.12

Pleomorphic liposarcoma

73

0.10

0.03

0.04

0.05

0.00

0.00

0.00

0.00

0.00

0.01

0.02

0.02

Liposarcoma, NOS

67

0.20

0.09

0.13

0.14

0.10

0.04

0.05

0.06

0.10

0.05

0.08

0.08

 Chondrosarcoma

55

0.50

0.32

0.41

0.40

0.40

0.30

0.36

0.36

0.50

0.34

0.41

0.41

 Dermatofibrosarcoma

44

0.40

0.31

0.35

0.35

0.50

0.40

0.45

0.44

0.40

0.37

0.42

0.41

 Kaposi sarcoma

63

0.60

0.40

0.52

0.54

0.10

0.04

0.06

0.06

0.30

0.20

0.27

0.28

 Angiosarcoma

73

0.20

0.10

0.15

0.16

0.40

0.17

0.25

0.27

0.30

0.16

0.23

0.25

 Osteosarcoma

34

0.30

0.34

0.33

0.33

0.30

0.25

0.24

0.25

0.30

0.28

0.27

0.27

 Ewing sarcoma

19

0.30

0.35

0.30

0.30

0.20

0.32

0.27

0.27

0.30

0.33

0.28

0.28

 Myxofibrosarcoma

66

0.30

0.16

0.22

0.22

0.20

0.10

0.14

0.14

0.20

0.14

0.19

0.19

 Rhabdomyosarcoma

25

0.30

0.26

0.24

0.25

0.20

0.21

0.18

0.18

0.20

0.25

0.22

0.23

Embryonal rhabdomyosarcoma

12

0.10

0.15

0.11

0.11

0.10

0.09

0.06

0.06

0.10

0.11

0.08

0.08

Alveolar rhabdomyosarcoma

22

0.00

0.05

0.04

0.04

0.00

0.08

0.06

0.06

0.00

0.05

0.04

0.04

Pleomorphic rhabdomyosarcoma

69

0.10

0.02

0.03

0.03

0.00

0.01

0.01

0.01

0.00

0.01

0.02

0.02

Spindle cell rhabdomyosarcoma

40

0.00

0.00

0.00

0.01

0.00

0.03

0.02

0.02

0.00

0.00

0.00

0.00

Rhabdomyosarcoma NOS

64

0.00

0.01

0.01

0.01

0.00

0.01

0.02

0.02

0.00

0.01

0.02

0.02

 Nerve Sheath Tumors

55

0.10

0.10

0.13

0.13

0.20

0.12

0.15

0.15

0.20

0.12

0.15

0.15

 Endometrial stromal sarcoma

62

–

–

–

–

0.30

0.17

0.23

0.23

0.30

0.17

0.23

0.23

 Synovial sarcoma

47

0.10

0.16

0.17

0.17

0.10

0.13

0.15

0.14

0.10

0.15

0.16

0.16

Spindle cell synovial sarcoma

49

0.1

0.07

0.05

0.05

0.10

0.05

0.06

0.06

0.10

0.05

0.07

0.07

Biphasic synovial sarcoma

44

0.0

0.00

0.00

0.00

0.00

0.02

0.01

0.01

0.00

0.00

0.00

0.00

Synovial sarcoma NOS

44

0.1

0.06

0.04

0.06

0.00

0.05

0.05

0.05

0.10

0.05

0.05

0.05

 Chordoma

61

0.20

0.11

0.14

0.15

0.10

0.06

0.08

0.08

0.10

0.09

0.12

0.12

 Solitary fibrous tumor. Malignant

63

0.10

0.11

0.14

0.13

0.10

0.08

0.10

0.10

0.10

0.10

0.12

0.12

 Fibrosarcoma

60

0.10

0.03

0.05

0.05

0.10

0.03

0.04

0.04

0.10

0.03

0.04

0.04

 Malignant myoepithelioma

56

0.00

0.03

0.04

0.04

0.00

0.03

0.04

0.04

0.00

0.03

0.04

0.04

 Epithelioid haemangioendothelioma

47

0.00

0.03

0.03

0.03

0.00

0.05

0.05

0.05

0.00

0.05

0.06

0.06

 Other (with fewer than 20 cases)

46

0.20

0.19

0.17

0.18

0.20

0.19

0.20

0.20

0.20

0.20

0.20

0.20

Total

63

7.60

5.27

6.54

6.80

7.20

4.81

5.83

5.90

7.40

5.00

6.12

6.26

  1. Abreviations: GIST Gastro-Intestinal Stromal Tumors, CIR Crude Incidence Rate per 100,000 persons-years, ASR-W, ASR-E and ASR-US Age-Standardized incidence Rate from three reference populations (W, World Segi; E, European; US, United-States)
  2. aUnclassified sarcomas include: Sarcoma not otherwise specified (ICDO-88003), undifferentiated spindle cell sarcoma (ICDO-88013), undifferentiated pleomorphic sarcoma (ICDO-88023), undifferentiated round cell sarcoma (ICDO-88033), epithelioid sarcoma (ICDO-88043), undifferentiated sarcoma NOS (ICDO-88053)
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us